Previous Article | Next Article 
Journal of Virology, November 2000, p. 10132-10141, Vol. 74, No. 21
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Herpes Simplex Virus Type 1 ICP0 Protein Does Not
Accumulate in the Nucleus of Primary Neurons in Culture
Xiao-Ping
Chen,1
Jia
Li,1
Marina
Mata,1,2
James
Goss,1
Darren
Wolfe,3
Joseph C.
Glorioso,3 and
David J.
Fink1,2,3,*
Departments of
Neurology1 and Molecular Genetics and
Biochemistry,3 University of Pittsburgh School
of Medicine, Pittsburgh, Pennsylvania 15213, and VA Medical
Center, Pittsburgh, Pennsylvania 152402
Received 2 May 2000/Accepted 9 August 2000
 |
ABSTRACT |
Infected-cell protein 0 (ICP0), the product of the herpes simplex
virus (HSV) immediate-early (IE)
0 gene, is a promiscuous transactivator of viral early (E) and late (L) gene expression. HSV
mutants lacking ICP0 function are severely deficient in viral growth
and protein synthesis, particularly at low multiplicities of infection.
Early in the infectious process in vitro, ICP0 protein accumulates in
distinct domains within the nucleus to form characteristic structures
active in the transcription of viral genes. However, following
infection of primary trigeminal ganglion cells in vitro with a
recombinant HSV mutant that expresses only ICP0, we observed that ICP0
protein accumulated in the characteristic intranuclear distribution
only in the nuclei of Schwann cells; neurons in the culture did not
accumulate ICP0 despite expression of ICP0 RNA in those cells. The same
phenomenon was observed in PC12 cells differentiated to assume a
neuronal phenotype. In primary neurons in culture, the amount of ICP0
protein could be increased by pharmacologic inhibition of
calcium-activated protease (calpain) activity or by inhibition of
protein phosphatase 2B (calcineurin). The failure of ICP0 protein to
accumulate in the nucleus of neurons suggests that one mechanism which
may impair efficient replication of the virus in neurons, and thus
favor the establishment of viral latency in those cells, may be found
in the cell-specific processing of that IE gene product.
 |
INTRODUCTION |
Herpes simplex virus type 1 (HSV-1)
is a double-stranded DNA virus with a broad host range. Viral gene
expression in lytic infection proceeds in a tightly regulated temporal
cascade of immediate-early (IE), early (E), and late (L) gene products
that are expressed sequentially (24, 60). Four of the viral
IE gene products (ICP0, ICP4, ICP22, and ICP27) act to regulate
subsequent viral gene expression at both transcriptional and
posttranscriptional levels (52, 53, 60). The initial
expression of IE genes in epithelial cells depends on binding of the
viral tegument protein VP16 to TAATGARAT sequences in the IE gene
promoter elements (26, 33, 34, 48), a process that requires
collaboration with host cell factors (Oct-1 and C1). In natural
infection, virions released after primary infection of epithelial cells
in skin or mucous membranes are carried by retrograde axonal transport
to the sensory ganglion, where the virus may replicate in neurons or
supporting cells but ultimately establishes a characteristic latent
state exclusively in the sensory neurons of the ganglion (22). HSV replicates efficiently in a wide variety of cell
types in a cell cycle-independent fashion, but replication is less
efficient in nondividing cells such as neurons (30, 46).
Several differences between neurons and other cell types may explain
the relatively inefficient replication of HSV in neurons. Because of
the limited availability of substrates required for DNA replication in
neurons, HSV must provide enzymes for the synthesis of those substrates (e.g., ribonucleotide reductase and thymidine kinase). Mutants that are
defective in these enzymes replicate normally in nonneuronal cells but
poorly or not at all in neurons (2, 10). Wild-type viral
replication also depends on cell-specific regulators of viral gene
expression that may have limited expression or restricted intracellular
distribution in neurons (35, 36) or the cell-specific expression of inhibitors of IE gene expression (28, 29). It has also been suggested previously that viral DNA synthesis may serve
as a critical regulatory branch point between the lytic and latent
pathways of infection in neurons (45).
Among the HSV IE genes, ICP0 is a potent promiscuous transactivator of
gene expression that has been demonstrated to stimulate expression of
HSV IE, E, and L genes, as well as a number of other eukaryotic genes,
in transient-transfection assays (16, 41, 49, 51). Although
ICP0 expression is not essential for HSV replication in Vero cells,
recombinant viruses with both copies of the ICP0 gene deleted show
greatly increased particle-to-PFU ratios, reduced expression of viral
IE proteins, and impaired viral replication, particularly at low
multiplicities of infection (MOIs) (6, 7, 14, 54, 58).
Extranuclear sites of ICP0 activity in the regulation of RNA
translation have been proposed elsewhere (27), but the
principal function of ICP0 as a transactivator of gene expression is a
function that requires ICP0 protein in the nucleus. In accord with this
function, newly synthesized ICP0 protein translocates early in
infection from the cytoplasm to the nucleus, where it accumulate in
discrete domains (19, 39) that appear to serve as the site
of initial viral genome deposition and early viral replication
(38, 40). These nuclear domains (ND10s), which can be
identified in uninfected cells by the presence of specific protein
components (9, 12), become disrupted and dispersed in an
ICP0-dependent fashion as lytic infection proceeds (18, 19).
ICP0 colocalizes with ICP4 in the nucleus of infected cells
(31), and ICP27 plays a critical role in determining the
localization of ICP0 protein (64, 65). But additional HSV IE
gene products are not required for ICP0 localization to the nucleus of
infected cells, as expression of ICP0 alone from a plasmid results in
the nuclear localization of the protein product (64).
We report here that, upon infection of primary neurons in culture, both
wild-type HSV and two HSV mutants designed to express only ICP0 in the
absence of other IE genes accumulate ICP0 protein within the nucleus
only of nonneuronal cells. The block to ICP0 protein accumulation is
not at the level of transcription, because ICP0 RNA can be detected
both by in situ hybridization and by single-cell reverse
transcription-PCR (RT-PCR) of infected neurons, but rather appears to
involve protein processing since pharmacologic blockade of either
calcium-activated protease (calpain) or protein phosphatase 2B
(calcineurin) results in the intranuclear accumulation of ICP0 in
neurons. ICP0 expression plays an important role in viral gene
transactivation and viral replication. The failure of ICP0 to
accumulate in the nucleus of neurons may be one factor that favors the
establishment of latency in neurons following viral infection.
 |
MATERIALS AND METHODS |
Virus constructs.
Wild-type virus infections were carried
out with a laboratory strain, KOS, of HSV-1. The construction of the
deletion mutant TOZ.1 has been described previously (32).
This viral recombinant has deletions of both copies of ICP4
(11), ICP22 (genomic positions 133372 to 133465), ICP27
(42), and the viral host shutoff gene UL41
(genomic positions 91606 to 92124) and has an ICP0
promoter::lacZ expression cassette in the
UL41 locus. The IE gene coding for ICP47 has been left
intact in this recombinant, and the ICP4 IE promoter has been
substituted for the native thymidine kinase promoter, resulting in a
disruption of the HSV UL24 gene. The recombinant was
propagated on ICP4-ICP27-producing 7B cells, purified by three rounds
of limiting dilution, and verified by Southern blotting
(32). A second mutant, QOZHG, was also used. The virus QOZHG
(ICP4
ICP27
::HCMV IEp-GFP
-ICP22
-ICP47 UL41
::ICP0p-lacZ) was created by
a genetic cross of the virus TOZ.1 (ICP4
ICP27
ICP22
UL24
::ICP4p-tk
UL41
::ICP0p-lacZ) with the virus d106
(ICP4
ICP27
::HCMV IEp-GFP
-ICP22
-ICP47; a kind gift of N. DeLuca, Pittsburgh, Pa.) (55).
Green fluorescent protein (GFP)-positive fluorescent plaques, which
stained blue with X-Gal
(5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside), were
purified by three rounds of limiting dilution. The genomic structure of
the QOZHG recombinant was confirmed by Southern blot analysis.
Cell culture.
Trigeminal ganglia (TG) from 17-day rat
embryos were dissociated with 0.25% trypsin-1 mM EDTA for 30 min at
37°C with constant shaking and then plated on
poly-D-lysine (molecular weight, 70,000 to 150,000; Sigma,
St. Louis, Mo.)-coated coverslips at 105 cells/well in a
24-well plate (Falcon, Lincoln Park, N.J.) in 500 µl of defined
NeuroBasal medium (GIBCO-BRL, Rockville, Md.) supplemented with 1×
B027 (GIBCO), 1× GlutaMAX (GIBCO), 0.5 µg of AlbuMAX II (GIBCO) per
ml, 100 U of penicillin per ml, and 100 ng of 7.0s nerve growth factor
(NGF) (Sigma) per ml. 5-Fluoro-2'-deoxyuridine (10 µM; Sigma) and
uridine (10 µM; Sigma) were added at day 8 to inhibit the growth of
dividing cells. The cells were infected at 10 days after plating in 250 µl of medium for 1 h at 37°C with gentle agitation every 20 min. PC12 cells (a gift of J. Chen, University of Pittsburgh) were
grown at 37°C in 10% CO2 in Dulbecco's modified Eagle
medium (GIBCO) supplemented with 7.5% fetal calf serum (GIBCO) and
7.5% horse serum (GIBCO) on rat tail collagen-coated tissue culture
dishes (Falcon) or on coated plastic coverslips (Sarstedt, Newton,
N.C.) in 24-well plates. PC12 cells were differentiated to assume a
neuronal phenotype by the addition of 100 ng of 2.5s NGF (Sigma) per ml
to culture medium containing 1% serum and plated at less than 2 × 104 cells/cm2. Cells were infected with
virus 7 days after NGF treatment, in a manner identical to that
described for dissociated TG cells.
Immunohistochemistry.
Cells were fixed in Histochoice
(Amresco, Solon, Ohio) for 20 min at room temperature (r.t.) and
incubated with the primary antibody at 1:1,000 in phosphate-buffered
saline (PBS) containing 1% goat serum for 2 h at r.t. or 4°C
overnight, followed by a Cy3-conjugated secondary antibody (1:3,000;
Sigma) for 1 h at r.t. The anti-ICP0 rabbit polyclonal antibody
was the kind gift of R. Courtney (Pennsylvania State University School
of Medicine), and the anti-HSV rabbit polyclonal antibody was purchased
from Accurate Chemical & Scientific Corp. (Westbury, N.Y.). For
detection of
-galactosidase expression, cells were fixed with 4%
paraformaldehyde for 10 min at r.t., rinsed for 5 min with PBS twice,
and then incubated in X-Gal (Promega, Madison, Wis.)-containing
solution for 2 h at 37°C. For detection of GFP, the cells were
fixed with 4% paraformaldehyde and observed under epifluorescence.
Images were acquired with a Xillix digital camera attached to a
personal computer-based image analysis system (MCID, St. Catharines,
Ontario, Canada) using the same settings for experimental cultures and mock-infected controls in each experiment.
In situ hybridization.
A plasmid containing the
PstI-MluI fragment in the BamHI
fragment B of HSV-1 spanning exon 3 of ICP0, obtained from J. Spivack, was linearized with EcoRI and transcribed with T7 RNA
polymerase using digoxigenin-UTP (Roche Boehringer Mannheim,
Indianapolis, Ind.) to label the transcript, followed by alkaline
hydrolysis. The length of the probe was between 200 and 800 bp. Cells
were fixed in 4% paraformaldehyde for 10 min, treated with 1% HCl in PBS for 5 min, and then acetylated with acetic anhydride in
triethanolamine for 10 min. After equilibration in 2× SSC (1× SSC is
0.15 M NaCl plus 0.015 M sodium citrate) for 5 min, the cells were
dehydrated in graded ethanols and air dried. Hybridization with the
digoxigenin-labeled riboprobe (0.5 µg/ml) was carried out overnight
at 56°C in 15 µl of hybridization solution (75% formamide, 10%
dextran sulfate, 2× SSC, 1× PBS, 1× Denhardt's solution, and 0.02%
tRNA). Following hybridization, the coverslips were rinsed three times
with 2× SSC for 5 min, digested with RNase A (200 µg/ml in 10 mM
Tris-HCl-0.5 M NaCl), rinsed sequentially with 2× SSC and 1× SSC at
56°C, and then washed for 1 h in 1× SSC at 56°C. After
blocking with 5% normal goat serum in PBS for 1 h, the
digoxigenin-labeled probe was localized with an alkaline
phosphatase-conjugated antidigoxigenin antibody (1:5,000; Boehringer
Mannheim) and detected with 5-bromo-4-chloro-3-indolylphosphate and
nitroblue tetrazolium.
Northern and Western blotting.
For protein detection, cells
were lysed in buffer (1× PBS, 1% NP-40, 0.5% sodium deoxycholate,
100 µg of phenylmethylsulfonyl fluoride per ml, and 20 µg of
leupeptin per ml), and the protein was separated on a sodium dodecyl
sulfate (SDS)-7.5% polyacrylamide gel, transferred to a
nitrocellulose membrane, and detected with the anti-ICP0 primary
antibody (1:1,000), followed by a peroxidase-conjugated secondary
antibody (1:5,000; Sigma) and chemiluminescence detection with ECL
(Amersham). Equivalent amounts of total protein were loaded in each
lane. Total RNA was extracted from infected cells using the RNeasy
minikit (Qiagen, Valencia, Calif.) according to the manufacturer's
instructions. Ten micrograms of total RNA per lane was separated in a
1.2% agarose gel containing 0.22 M formaldehyde, transferred to a
GeneScreen Plus membrane (NEN, Boston, Mass.), fixed by UV
cross-linking, washed in 1% SDS-1× SSC at 77°C for 30 min,
prehybridized in hybridization solution [5× SSC, 1% SDS, 10%
dextran sulfate, 0.5% dry milk, 25 µg of poly(A) per ml, 25 µg of
poly(C) per ml, 200 µg of sheared salmon sperm DNA per ml), and then
hybridized overnight at 77°C with the [32P]CTP-labeled
ICP0 riboprobe (2 × 106 cpm/ml). The radioactive
riboprobe for ICP0 was prepared using the same methods described above
for the digoxigenin-labeled probe that was used for the in situ
hybridization, except that the alkaline hydrolysis step was omitted.
Following hybridization, the membrane was washed for 1 h at 77°C
in 5× SSC-0.5% dry milk-1% SDS, twice for 30 min in 2× SSC-0.1%
SDS, and twice for 30 min in 0.5× SSC at 77°C. The radioactively
labeled probe was detected with a phosphorimager (Molecular Dynamics,
Sunnyvale, Calif.).
Single-cell RT-PCR for ICP0.
Individual infected trigeminal
neurons identified by the expression of GFP were isolated in a pulled
and beveled microcapillary using a Burleigh MIS-5000 micromanipulator
(Fisher, New York, N.Y.) and an IM-6-2 microinjector (Narishige, Tokyo,
Japan). The single cells were individually placed into thin-walled PCR
tubes (Perkin-Elmer, Foster City, Calif.) containing 21 µl of cell
lysis buffer (0.5% NP-40 and 10 U of RNase inhibitor). Lysis was
accomplished by one round of freezing and thawing followed by
incubation for 5 min at 72°C. Seven microliters of the single-cell
lysate was saved for RT control, and RT was performed on the remaining
13 µl using the Sensiscript reverse transcriptase kit from Qiagen. Briefly, the RT reaction was performed for 1 h at 37°C by
addition of 1× RT buffer containing 0.5 mM (each) dATP, dCTP, dGTP,
and dTTP; 10 U of RNase inhibitor; 2.5 µM random hexamer
(Perkin-Elmer); and 1 µl of Sensiscript reverse transcriptase. The
reaction was terminated by incubation at 95°C for 5 min followed by
rapid chilling on ice. PCR was then carried out in a 100-µl reaction
volume using a hot-start PCR kit from Qiagen. Of the RT product (cDNA),
10 to 20% was used in a PCR containing 1× PCR buffer; 2 mM
MgCl2; 200 µM (each) dATP, dCTP, dGTP, and dTTP; 0.2 µM
primers; 2.5 U of HotStarTaq DNA polymerase; and 10 µCi of
[32P]dCTP. The PCR was performed in a Perkin-Elmer
Thermal Cycler 480 and consisted of a 15-min preincubation at 95°C;
40 cycles of denaturing (94°C, 1 min), annealing (60°C, 1 min), and
extension (72°C, 1 min); and final extension for 10 min at 72°C.
The PCR product was separated on a 5% acrylamide gel and detected by
autoradiography. The appropriate size of the product was determined by
comparison to a positive-control PCR product. The primers used for
mouse
-actin and ICP0 were chosen because the size of the product
distinguishes RNA-derived signal (intron absent, short amplification
product) from genomic DNA-derived signal (intron present, larger
product). The oligonucleotide primer pairs were as follows:
-actin
(amplification fragment, 359 bp), 5'-GGTTCCGATGCCCTGAGGCTC-3'
(sense) and 5'-ACTTGCGGTGCACGATGGAGG-3' (antisense);
ICP0 (amplification fragment, 157 bp), 5'-TTCGGTCTCCGCCTGAGAGT-3' (sense) and 5'-GACCCTCCAGCCGCATACGA-3' (antisense), as
described in reference 37.
Inhibitor treatment.
TG cultures were pretreated for 4 h with the lysosome inhibitor choloroquine (Sigma), the calpain
inhibitor PD 150606 (5 µM; Calbiochem, La Jolla, Calif.), or the
proteasome inhibitor lactacystin (10 µM; Calbiochem). PD 150606 and
lactacystin were dissolved in 100% dimethyl sulfoxide (Sigma) first
and then added into the tissue culture solution at less than 1% of
total volume. The cells were then washed twice with Dulbecco's
modified Eagle medium and infected with QOZHG virus at an MOI of 5 for
1 h. The virus-containing medium was then replaced with medium
containing the inhibitors (or the same concentration of dimethyl
sulfoxide alone for the controls) for an overnight incubation. For
inhibition of calcineurin activity, cyclosporine (200 ng/ml; Novartis,
East Hanover, N.J.) was added into the culture medium 12 h after
infection (MOI of 5), and the experiment was terminated 4 h later.
 |
RESULTS |
ICP0 accumulates in the nucleus of Schwann cells but not in the
nucleus of primary neurons in culture.
Dissociated TG cultures
contain a mixed population of neurons, identified by their
characteristic morphology and immunostaining for neuron-specific
proteins including the neuronal isoform of microtubule-associated
protein 2 (MAP2) and neurofilament proteins and supporting cells that
include Schwann cells, satellite cells, and fibroblasts. Infection of
these cultures with either wild-type virus or the nonneurotoxic
ICP0-expressing recombinant TOZ or QOZHG at an MOI of 5 resulted in the
expression of ICP0 protein in the characteristic punctate
intranuclear distribution exclusively in nonneuronal cells, not
in neurons (Fig. 1). The majority
of both neurons and Schwann cells in the culture were infected, as determined by X-Gal staining for lacZ expression (Fig.
2, inset). Neurons are clearly defined in
these cultures by the characteristic morphology and the presence of a
bright halo on phase microscopy, and the identity of the
ICP0-immunoreactive cells as nonneuronal was confirmed by
immunocytochemical staining of neurons with an antibody to MAP2 (Fig.
2). The amount of ICP0 immunoreactivity increased over the first 8 h of infection and then remained unchanged from 16 to 24 h
postinfection after infection with the replication-incompetent mutant
TOZ (data not shown). Similar results were found 5 h after infection of the cultures with wild-type KOS, where the ICP0
accumulated in the nucleus of Schwann cells but not in neurons despite
the widespread infection of both neurons and Schwann cells in the culture (Fig. 3). The distribution of
ICP0 at later time points after infection with replicating virus could
not be determined because of the cytolytic effects of the replicating
virus. No ICP0 immunoreactivity was seen with mock-infected cells.

View larger version (82K):
[in this window]
[in a new window]
|
FIG. 1.
ICP0 protein accumulates in the nuclei of nonneuronal
cells in dissociated TG cultures. Sixteen hours after infection with
TOZ (MOI of 5), ICP0 is found in the nucleus of Schwann cells
(arrowheads) but not neurons (arrow, identified by the characteristic
appearance) in the cultures (phase contrast [A], fluorescence [B],
and merged image [C]). At higher power, the immunostaining in the
nucleus of the nonneuronal cells has the characteristic punctate
appearance as described previously (D). ICP0 RNA can be detected in
infected neurons by in situ hybridization with a digoxigenin-labeled
riboprobe (inset, panel A).
|
|

View larger version (87K):
[in this window]
[in a new window]
|
FIG. 2.
ICP0 does not accumulate in the nucleus of neurons in
culture. The identity of the neurons was confirmed by immunostaining
with an antibody to the neuron-specific antigen MAP2 (C and D). TOZ (A
and C)- and mock (B and D)-infected cultures, 16 h postinfection,
show ICP0 in a punctate pattern in the nucleus of Schwann cells but not
of neurons in the infected cultures (A and C). X-Gal staining (inset,
panel C) demonstrates that the majority of the cells in the culture,
including neurons, were infected and expressed the lacZ
transgene. Panels A and B are fused phase and fluorescent images of
cultures counterstained with DAPI (4',6'-diamidino-2-phenylindole).
|
|

View larger version (97K):
[in this window]
[in a new window]
|
FIG. 3.
The pattern of accumulation of ICP0 after infection with
replicating virus is similar to the pattern seen after infection with
TOZ. Five hours after infection with wild-type KOS (MOI of 5), ICP0 is
demonstrated by immunohistochemistry in the nucleus of nonneuronal
cells (B) but is not seen in neurons (arrows, panels A and B).
Wild-type KOS infected virtually all the cells in the culture,
demonstrated by robust expression of HSV gC in neurons (D). Panels A
and C are the phase micrographs corresponding to the fluorescent images
in panels B and D.
|
|
ICP0 RNA is expressed in neurons.
ICP0 RNA could be detected
by in situ hybridization in a small number of infected neurons (Fig. 1,
inset) despite the absence of ICP0 protein staining. However, a much
greater proportion of neurons were infected, as determined by X-Gal
staining and GFP expression, than expressed ICP0 RNA detectable by in
situ hybridization. We therefore proceeded to use single-cell RT-PCR to
explore whether ICP0 RNA could be detected in individual infected
neurons. For these experiments, the TG cultures were infected with
QOZHG, which, like recombinant TOZ, does not express ICP4, ICP22, or
ICP27 and has ICP41 (viral host shutoff function) deleted but in
addition has the GFP under the control of the human
cytomegalovirus IEp allowing us to identify infected neurons in
culture. Eighteen hours after infection with QOZHG, infected
GFP-expressing neurons identified by their characteristic green
fluorescence (approximately 80% of the neurons in the culture appeared
to express GFP) were individually removed from the coverslip using a
micropipette, and the RNA from the isolated cell was prepared for RT of
-actin or ICP0 using primers specific for the RNA. In this
experiment (which was repeated twice),
-actin RNA could be detected
in approximately half (6 of 12 and 7 of 16) of the individual cells
that were examined, and ICP0 RNA was detected in half (three of six and
three of seven) of the
-actin-positive samples (Fig.
4). These data suggest that at least half
of the infected neurons in the culture express ICP0 RNA, despite the
fact that ICP0 immunostaining was rarely found in neurons.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 4.
ICP0 RNA can be detected in approximately half of
individual infected neurons by single-cell RT-PCR of infected neurons.
Individual infected neurons identified by green fluorescence were
isolated, and RT-PCR for -actin was used to confirm RNA recovery.
Approximately 50% of -actin RNA-positive cells also showed ICP0 RNA
by RT-PCR. Each lane represents the results of PCR amplification of
cDNA obtained from a single identified infected cell in which -actin
was detected (upper panels). Results from four representative infected
cells, two with detectable ICP0 RNA (lanes 1 and 2) and two without
detectable ICP0 RNA (lanes 3 and 4), are shown. All of the uninfected
cells (identified by the absence of fluorescence) in which -actin
RNA was detected were negative for ICP0 RNA (data not shown).
|
|
The accumulation of ICP0 protein is reduced in differentiated PC12
cells compared to undifferentiated PC12 cells.
PC12 cells can be
stimulated to assume a neuronal phenotype by exposure to NGF.
Undifferentiated PC12 cells infected with wt virus or TOZ at
an MOI of 3 demonstrated the punctate nuclear distribution similar to
that seen with nonneuronal cells in TG cultures (Fig.
5). In contrast, differentiated PC12
cells showed only diffuse staining that was barely distinguishable from
that of control uninfected cells stained in a similar fashion (Fig. 6). The difference in protein expression
and distribution did not result from a failure of infection or
transcription. The vast majority of cells in both differentiated and
undifferentiated PC12 cell cultures were infected by TOZ as
demonstrated by X-Gal staining for lacZ expression (Fig. 5
and 6, insets). A single 2.7-kb band of ICP0 RNA was isolated from
infected undifferentiated and differentiated PC12 cell cultures, and
similar amounts were detected in infected differentiated and
undifferentiated PC12 cell cultures as determined by Northern blotting
(Fig. 7A). By Western
blotting, ICP0 protein could be detected as a single 110-kDa band in
both differentiated and undifferentiated cultures, but the amount was
less in infected differentiated than in undifferentiated cultures (Fig.
7B). These results suggested that the rate of RNA synthesis is similar
in differentiated and undifferentiated cells, but that protein turnover
is more rapid in differentiated PC12 cells.

View larger version (73K):
[in this window]
[in a new window]
|
FIG. 5.
ICP0 protein accumulates in a punctate nuclear pattern
in undifferentiated PC12 cells. Undifferentiated PC12 cells 16 h
postinfection with TOZ (A and C) show the punctate nuclear pattern of
ICP0 immunohistochemistry characteristic of nonneuronal cells.
Virtually all the cells have been infected as demonstrated by X-Gal
staining (inset, panel C). Mock-infected cultures are shown in panels B
and D. (A and B) Phase microscopy. (C and D) Fluorescence.
|
|

View larger version (83K):
[in this window]
[in a new window]
|
FIG. 6.
ICP0 fails to accumulate in the nucleus of
differentiated PC12 cells. PC12 cells differentiated by exposure to NGF
to assume a neuronal phenotype show only faint diffuse cytoplasmic
immunostaining 16 h after infection with TOZ (C). Mock-infected
cultures are shown in panels B and D. Virtually all the cells have been
infected as demonstrated by X-Gal staining (inset, panel C). (A and B)
Phase microscopy. (C and D) Fluorescence.
|
|

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 7.
ICP0 RNA is expressed in both differentiated and
undifferentiated PC12 cells, but the amount of protein is reduced in
differentiated cells. Undifferentiated (UNDIFF) or differentiated
(DIFF) PC12 cells were infected with TOZ at an MOI of 5, and RNA and
protein were extracted 16 h after infection. Representative
Northern (A) and Western (B) blots of RNA and protein from the infected
(INF) and mock-infected PC12 cells are shown. The experiment was
independently repeated four times, with similar results.
|
|
ICP0 protein accumulation in neurons is increased by inhibition of
calcineurin or calpains in culture.
Because the combined data from
the PC12 cell and TG culture experiments suggested that ICP0 RNA was
expressed in both neuronal and nonneuronal cells but that the protein
failed to accumulate in the nucleus in either neurons or in PC12 cells
that had been differentiated to a neuronal phenotype, we examined the
effect of adding inhibitors of proteolysis to infected cell cultures. There is evidence that proteasome activity is required to stimulate the
progression of HSV infection (20), but inhibition of the proteasome pathway with lactacystin did not increase the number of
neurons exhibiting intracellular accumulation of ICP0 protein (17 of
1,400 neurons counted on a single well). However, inhibition of calpain
activity by PD 150606 resulted in a dramatic increase in the number of
neurons that accumulated ICP0 (320 of 800 in a single culture). The
amount of ICP0 increased in both the nucleus and the cytoplasm and
accumulated in aggregates in both sites, and it appeared in most cases
that ICP0 accumulated in the nucleus first and then in the cytoplasm,
since many cells had nuclear or nuclear and cytoplasmic ICP0 but almost
none demonstrated significant cytoplasmic accumulation in the absence
of ICP0 in the nucleus. Similar effects were achieved by the inhibition
of protein phosphatase 2B (calcineurin) by the addition of cyclosporine
(632 of 1,380 neurons counted). Both inhibition of proteolysis and
inhibition of phosphatase resulted in a punctate pattern of ICP0 in the
nucleus and accumulation of aggregates of ICP0 in the cytoplasm as well (Fig. 8 and
9).

View larger version (82K):
[in this window]
[in a new window]
|
FIG. 8.
Inhibition of calpain activity results in accumulation
of ICP0 in neurons. Sixteen hours after infection of primary TG
cultures with QOXHG at an MOI of 5, little immunoreactivity is seen in
untreated neurons (arrowheads, panels A and B). Neurons (arrowheads)
treated with PD 150606 to inhibit calpain activity show marked nuclear
and cytoplasmic accumulation of immunoreactive ICP0 protein (C and D).
Panels A and C show the phase micrographs corresponding to the
fluorescent immunocytochemical images shown in panels B and D.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 9.
Inhibition of calcineurin activity results in
accumulation of ICP0 in neurons. Sixteen hours after infection of
primary TG cultures with recombinant QOZHG at an MOI of 5, no ICP0
immunoreactivity is seen in infected neurons (arrowheads). One neuron,
identified by its characteristic morphology and identified as infected
by the expression of GFP, is shown in panels A and B. A Schwann cell in
the same culture is seen in the lower left of those panels. TG cultures
treated with cyclosporine to inhibit calcineurin activity show marked
accumulation of ICP0 in the nucleus and cytoplasm of infected neurons
(arrowheads, panels C and D). Panels A and C are fluorescent
micrographs of GFP expression. Panels B and D are cultures stained for
ICP0.
|
|
 |
DISCUSSION |
The early localization of ICP0 in a punctate pattern in the
nucleus of infected cells is characteristic of HSV infection. Because
of the important role that ICP0 plays as a transcriptional regulator of
HSV gene expression, and the evidence that ICP0 mutants that are
impaired in their ability to accumulate in the nucleus replicate poorly
(14), nuclear localization of the protein is likely to be
important in the regulation of that function. The observation that in
neurons (and PC12 cells differentiated to a neuronal phenotype) ICP0
protein does not accumulate in the nucleus identifies one important
cell-specific aspect of HSV IE gene product behavior that is different
in neurons compared to other cells.
Nuclear ICP0 colocalizes with nuclear substructures (ND10s)
recognizable by specific immunostaining for Sp100, identified by
antiserum obtained from patients with primary biliary cirrhosis, or
PML, identified by the presence of antibodies to it in acute promyelocytic leukemia and a fusion partner of the retinoic acid receptor, as well several other proteins (reviewed in reference 38). ND10s are found in a wide variety of cell types
but are not ubiquitous. In particular, these structures are absent from neurons and cell lines of neuronal lineage (9). It has been suggested that association of viral genomes and newly transcribed proteins with proteins in ND10 loci may promote the replication of HSV
genomes in those cells. HSV-associated ubiquitin-specific protease,
which binds strongly to ICP0 and removes ubiquitin adducts from
proteins, is an important component of ND10s (21). The ability of ICP0 to bind to HSV-associated ubiquitin-specific protease has been suggested to play a role in the activation of gene expression and stimulation of virus replication (20), since the
disruption of ND10s which occurs during HSV infection correlates with
ICP0 and proteasome-dependent degradation of several PML isoforms
(18). Although in transient-transfection assays ICP0
accumulates in a punctate nuclear distribution that includes but is not
exclusive to immunocytochemically defined ND10s (50), viral
RNA is found associated with ND10 before protein synthesis
(40), which appears to serve as an early site of DNA virus
deposition for HSV, adenovirus, and cytomegalovirus (1, 25).
Indirect evidence strongly supports the conclusion that these nuclear
structures play an important role in viral replication (38).
However, the lack of ND10 structures in neurons cannot account for the
failure of ICP0 protein to accumulate in punctate structures in
neurons, because increasing the amount of ICP0 protein by inhibition of
either calpains, lysosomal enzymes, or calcineurin activity in neurons
allows ICP0 to accumulate in the characteristic punctate intranuclear
pattern in those cells.
Could the absence of ICP0 in the nucleus of cells with the neuronal
phenotype result from alternative splicing of the gene product? The
ICP0 gene has three coding sequences; the second exon encodes a zinc
binding ring finger domain, while the third exon encodes sequences
which are required for nuclear localization (13, 15) and the
subsequent transactivation of viral gene expression (15).
Failure to splice out the second intron results in a product of 262 residues and a predicted molecular mass of 41 kDa which has a
dominant-negative effect on viral gene transcription in
transient-transfection assays (61, 62) and which is found after HSV infection of cell types in varying amounts (17).
However, it is not likely that alternative splicing in differentiated
PC12 cells accounts for the failure of ICP0 to accumulate in the
nucleus of neurons or PC12 cells differentiated to a neuronal
phenotype, because only a single protein band of 105 kDa was found in
infected PC12 cultures, whether differentiated or undifferentiated.
Analysis of the first intron demonstrates the existence of four
alternative splice variants (8). In addition to the
full-length 775-codon mRNA, the variant proteins are predicted to
contain 152, 90, and 87 amino acids. None of these smaller splice
variants were identified by Western blotting of infected PC12 cultures.
It therefore seems unlikely that alternative splicing accounts for the
difference in distribution of ICP0 between neuronal and nonneuronal
cells. A temperature-sensitive mutant ICP4 protein prevents the nuclear localization of ICP0 (31), but in the current experiments,
we have used an ICP4-deletion virus, and nuclear localization in nonneuronal cells infected with this recombinant is unimpaired.
ICP0 protein is extensively modified by posttranslational
phosphorylation and nucleotidylylation (3, 4, 43). UL13 contributes to, but is not the sole kinase responsible for, ICP0 phosphorylation (47), and posttranslational processing of
ICP0 varies from cell line to cell line. The observation that
inhibition of phosphatase activity increases the amount of ICP0 protein
in the cell, with accumulation in punctate aggregates both within the
nucleus and within the cytoplasm, suggests that phosphorylation may
protect newly synthesized ICP0 from rapid degradation, both in neurons
and in nonneuronal cells. Phosphorylation is a common pathway used to
protect cellular proteins from a variety of degradation pathways, as
has been demonstrated previously for structural proteins (23), enzymes involved in signal transduction
(5), and transcriptional regulators (44). We have
not directly demonstrated that phosphorylation protects ICP0 from
degradation; similar accumulation of increased amounts of ICP0 was
observed after inhibition of calcium-activated neutral protease
activity, which suggests that calpain activity may be one major path of
ICP0 degradation, particularly in neurons. Importantly, no protection
was afforded by the complete block of the proteasome pathway.
This report is limited to observations of ICP0 distribution in neurons
and other cells in culture. As with the situation in tissue culture, we
did not observe intranuclear ICP0 immunostaining in neurons in vivo at
1 to 5 days following infection by corneal scarification (data not
shown). However, this negative finding is difficult to interpret
because the punctate pattern of ICP0 immunostaining that has been
reported in many different cell types in culture has not been described
(and was not observed by us) even in nonneuronal cells in the TG in
vivo. Pharmacologic manipulations that increase ICP0 accumulation in
neuronal nuclei in vitro are not possible in vivo. Nonetheless, our
observations add to the substantial published literature regarding ICP0
distribution in cells in vitro, illuminating a potentially important
difference between neurons and nonneuronal cells in this regard.
The biology of HSV infection is cell type specific, although the
molecular mechanisms underlying this specificity have not been fully
established. Both primary neurons (59) and neuroblastoma cells (30) in culture are markedly nonpermissive for HSV
infection, defined by cytopathic effect and antigen expression. There
is substantial evidence that cell-specific transcriptional regulatory activators (26, 34) or inhibitors may influence the
expression of HSV IE genes in early infection (28, 29), but
the subcellular localization of cellular gene products may also
regulate HSV infection. It has recently been reported, for instance,
that the C1 host cell factor, an intranuclear protein which
collaborates in enhancing viral IE gene expression in a wide variety of
cell types, is redistributed from the cytoplasm to the nucleus of
neurons under the influence of stimuli that reactivate latent HSV
genomes (35). The failure of the ICP0 protein to accumulate
in the nucleus of neurons may play a similar role in the primary
infection. Herpesviruses characteristically naturally establish a life
long latent state in neurons, and a pseudolatent state can be
established in nonneuronal cells in vitro by preventing the virus from
replicating during initial infection (56, 57, 63). The
failure of ICP0 to translocate to the nucleus of neurons suggests a
potential mechanism for the inhibition of HSV replication in neurons
that may favor the establishment of a latent state in those cells.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from the NIH (J.C.G. and
D.J.F.), the Department of Veteran's Affairs (M.M. and D.J.F.), and
the GenVec Corporation (J.C.G. and D.J.F.).
We acknowledge the excellent technical assistance of XiaoPing Hu in
cell culture and immunocytochemistry and of Simon Watkins in imaging.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: S-520 BST, 200 Lothrop St., Pittsburgh, PA 15213. Phone: (412) 648-9793. Fax: (412) 648-8081. E-mail: dfink{at}med.pitt.edu.
 |
REFERENCES |
| 1.
|
Ahn, J. H., and G. S. Hayward.
1997.
The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells.
J. Virol.
71:4599-4613[Abstract].
|
| 2.
|
Aurelian, L.,
H. Kokuba, and C. Smith.
1999.
Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase.
Vaccine
17:1951-1963[CrossRef][Medline].
|
| 3.
|
Blaho, J. A.,
C. Mitchell, and B. Roizman.
1994.
An amino acid sequence shared by the herpes simplex virus 1 alpha regulatory proteins 0, 4, 22, and 27 predicts the nucleotidylylation of the UL21, UL31, UL47, and UL49 gene products.
J. Biol. Chem.
269:17401-17410[Abstract/Free Full Text].
|
| 4.
|
Blaho, J. A.,
C. Mitchell, and B. Roizman.
1993.
Guanylylation and adenylylation of the alpha regulatory proteins of herpes simplex virus require a viral beta or gamma function.
J. Virol.
67:3891-3900[Abstract/Free Full Text].
|
| 5.
|
Brondello, J. M.,
J. Pouyssegur, and F. R. McKenzie.
1999.
Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation.
Science
286:2514-2517[Abstract/Free Full Text].
|
| 6.
|
Cai, W., and P. A. Schaffer.
1992.
Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells.
J. Virol.
66:2904-2915[Abstract/Free Full Text].
|
| 7.
|
Cai, W. Z., and P. A. Schaffer.
1989.
Herpes simplex virus type 1 ICP0 plays a critical role in the de novo synthesis of infectious virus following transfection of viral DNA.
J. Virol.
63:4579-4589[Abstract/Free Full Text].
|
| 8.
|
Carter, K. L., and B. Roizman.
1996.
Alternatively spliced mRNAs predicted to yield frame-shift proteins and stable intron 1 RNAs of the herpes simplex virus 1 regulatory gene alpha 0 accumulate in the cytoplasm of infected cells.
Proc. Natl. Acad. Sci. USA
93:12535-12540[Abstract/Free Full Text].
|
| 9.
|
Cho, Y.,
I. Lee,
G. G. Maul, and E. Yu.
1998.
A novel nuclear substructure, ND10: distribution in normal and neoplastic human tissues.
Int. J. Mol. Med.
1:717-724[Medline].
|
| 10.
|
Coen, D. M.,
M. Kosz-Vnenchak, and J. G. Jacobsen.
1989.
Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.
Proc. Natl. Acad. Sci. USA
86:4736-4740[Abstract/Free Full Text].
|
| 11.
|
DeLuca, N. A.,
A. M. McCarthy, and P. A. Schaffer.
1985.
Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4.
J. Virol.
56:558-570[Abstract/Free Full Text].
|
| 12.
|
Dyck, J. A.,
G. G. Maul,
W. H. Miller, Jr.,
J. D. Chen,
A. Kakizuka, and R. M. Evans.
1994.
A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein.
Cell
76:333-343[CrossRef][Medline].
|
| 13.
|
Everett, R. D.
1988.
Analysis of the functional domains of herpes simplex virus type 1 immediate-early polypeptide Vmw110.
J. Mol. Biol.
202:87-96[CrossRef][Medline].
|
| 14.
|
Everett, R. D.
1989.
Construction and characterization of herpes simplex virus type 1 mutants with defined lesions in immediate early gene 1.
J. Gen. Virol.
70:1185-1202[Abstract/Free Full Text].
|
| 15.
|
Everett, R. D.
1987.
A detailed mutational analysis of Vmw110, a trans-acting transcriptional activator encoded by herpes simplex virus type 1.
EMBO J.
6:2069-2076[Medline].
|
| 16.
|
Everett, R. D.
1984.
Transactivation of transcription by herpes virus products: requirement for two HSV-1 immediate-early polypeptides for maximum activity.
EMBO J.
3:3135-3141[Medline].
|
| 17.
|
Everett, R. D.,
A. Cross, and A. Orr.
1993.
A truncated form of herpes simplex virus type 1 immediate-early protein Vmw110 is expressed in a cell type dependent manner.
Virology
197:751-756[CrossRef][Medline].
|
| 18.
|
Everett, R. D.,
P. Freemont,
H. Saitoh,
M. Dasso,
A. Orr,
M. Kathoria, and J. Parkinson.
1998.
The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms.
J. Virol.
72:6581-6591[Abstract/Free Full Text].
|
| 19.
|
Everett, R. D., and G. G. Maul.
1994.
HSV-1 IE protein Vmw110 causes redistribution of PML.
EMBO J.
13:5062-5069[Medline].
|
| 20.
|
Everett, R. D.,
M. Meredith, and A. Orr.
1999.
The ability of herpes simplex virus type 1 immediate-early protein Vmw110 to bind to a ubiquitin-specific protease contributes to its roles in the activation of gene expression and stimulation of virus replication.
J. Virol.
73:417-426[Abstract/Free Full Text].
|
| 21.
|
Everett, R. D.,
M. Meredith,
A. Orr,
A. Cross,
M. Kathoria, and J. Parkinson.
1997.
A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein.
EMBO J.
16:1519-1530[CrossRef][Medline].
|
| 22.
|
Fink, D. J.,
N. A. DeLuca, and J. C. Glorioso.
1996.
Gene transfer to neurons using herpes simplex virus-based vectors.
Annu. Rev. Neurosci.
19:265-287[CrossRef][Medline].
|
| 23.
|
Greenwood, J. A.,
J. C. Troncoso,
A. C. Costello, and G. V. Johnson.
1993.
Phosphorylation modulates calpain-mediated proteolysis and calmodulin binding of the 200-kDa and 160-kDa neurofilament proteins.
J. Neurochem.
61:191-199[CrossRef][Medline].
|
| 24.
|
Honess, R. W., and B. Roizman.
1974.
Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins.
J. Virol.
14:8-19[Abstract/Free Full Text].
|
| 25.
|
Ishov, A. M., and G. G. Maul.
1996.
The periphery of nuclear domain 10 (ND10) as site of DNA virus deposition.
J. Cell Biol.
134:815-826[Abstract/Free Full Text].
|
| 26.
|
Jones, K. A., and R. Tjian.
1985.
Sp1 binds to promoter sequences and activates herpes simplex virus `immediate-early' gene transcription in vitro.
Nature
317:179-182[CrossRef][Medline].
|
| 27.
|
Kawaguchi, Y.,
R. Bruni, and B. Roizman.
1997.
Interaction of herpes simplex virus 1 regulatory protein ICP0 with elongation factor 1 : ICP0 affects translational machinery.
J. Virol.
71:1019-1024[Abstract].
|
| 28.
|
Kemp, L. M.,
C. L. Dent, and D. S. Latchman.
1990.
Octamer motif mediates transcriptional repression of HSV immediate-early genes and octamer-containing cellular promoters in neuronal cells.
Neuron
4:215-222[CrossRef][Medline].
|
| 29.
|
Kemp, L. M., and D. S. Latchman.
1989.
Regulated transcription of herpes simplex virus immediate-early genes in neuroblastoma cells.
Virology
171:607-610[CrossRef][Medline].
|
| 30.
|
Kennedy, P. G.,
G. B. Clements, and S. M. Brown.
1983.
Differential susceptibility of human neural cell types in culture to infection with herpes simplex virus.
Brain
106:101-119[Abstract/Free Full Text].
|
| 31.
|
Knipe, D. M., and J. L. Smith.
1986.
A mutant herpesvirus protein leads to a block in nuclear localization of other viral proteins.
Mol. Cell. Biol.
6:2371-2381[Abstract/Free Full Text].
|
| 32.
|
Krisky, D. M.,
P. C. Marconi,
T. J. Oligino,
R. J. Rouse,
D. J. Fink,
J. B. Cohen,
S. C. Watkins, and J. C. Glorioso.
1998.
Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications.
Gene Ther.
5:1517-1530[CrossRef][Medline].
|
| 33.
|
Kristie, J., and B. Roizman.
1987.
Host cell protein binds to the cis-acting site required for virion-mediated induction of herpes simplex virus 1 genes.
Proc. Natl. Acad. Sci. USA
84:71-75[Abstract/Free Full Text].
|
| 34.
|
Kristie, T. M., and B. Roizman.
1986.
DNA-binding site of major regulatory protein 4 specifically associated with the promoter-regulatory domains of a genes of herpes simplex virus type I.
Proc. Natl. Acad. Sci. USA
83:4700-4704[Abstract/Free Full Text].
|
| 35.
|
Kristie, T. M.,
J. L. Vogel, and A. E. Sears.
1999.
Nuclear localization of the C1 factor (host cell factor) in sensory neurons correlates with reactivation of herpes simplex virus from latency.
Proc. Natl. Acad. Sci. USA
96:1229-1233[Abstract/Free Full Text].
|
| 36.
|
Lillycrop, K. A.,
Y. Z. Liu,
T. Theil,
T. Moroy, and D. S. Latchman.
1995.
Activation of the herpes simplex virus immediate-early gene promoters by neuronally expressed POU family transcription factors.
Biochem. J.
307:581-584.
|
| 37.
|
Lynas, C.,
K. A. Laycock,
S. D. Cook,
T. J. Hill,
W. A. Blyth, and N. J. Maitland.
1989.
Detection of herpes simplex virus type 1 gene expression in latently and productively infected mouse ganglia using the polymerase chain reaction.
J. Gen. Virol.
70:2345-2355[Abstract/Free Full Text].
|
| 38.
|
Maul, G. G.
1998.
Nuclear domain 10, the site of DNA virus transcription and replication.
Bioessays
20:660-667[CrossRef][Medline].
|
| 39.
|
Maul, G. G.,
H. H. Guldner, and J. G. Spivack.
1993.
Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0).
J. Gen. Virol.
74:2679-2690[Abstract/Free Full Text].
|
| 40.
|
Maul, G. G.,
A. M. Ishov, and R. D. Everett.
1996.
Nuclear domain 10 as preexisting potential replication start sites of herpes simplex virus type-1.
Virology
217:67-75[CrossRef][Medline].
|
| 41.
|
Mavromara-Nazos, P.,
S. Silver,
J. Hubenthal-Voss,
J. L. McKnight, and B. Roizman.
1986.
Regulation of herpes simplex virus 1 genes: alpha gene sequence requirements for transient induction of indicator genes regulated by beta or late (gamma 2) promoters.
Virology
149:152-164[CrossRef][Medline].
|
| 42.
|
McCarthy, A. M.,
L. McMahan, and P. A. Schaffer.
1989.
Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient.
J. Virol.
63:18-27[Abstract/Free Full Text].
|
| 43.
|
Mitchell, C.,
J. A. Blaho, and B. Roizman.
1994.
Casein kinase II specifically nucleotidylylates in vitro the amino acid sequence of the protein encoded by the alpha 22 gene of herpes simplex virus 1.
Proc. Natl. Acad. Sci. USA
91:11864-11868[Abstract/Free Full Text].
|
| 44.
|
Musti, A. M.,
M. Treier, and D. Bohmann.
1997.
Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases.
Science
275:400-402[Abstract/Free Full Text].
|
| 45.
|
Nichol, P. F.,
J. Y. Chang,
E. M. Johnson, Jr., and P. D. Olivo.
1996.
Herpes simplex virus gene expression in neurons: viral DNA synthesis is a critical regulatory event in the branch point between the lytic and latent pathways.
J. Virol.
70:5476-5486[Abstract/Free Full Text].
|
| 46.
|
Nichol, P. F.,
J. Y. Chang,
E. M. Johnson, Jr., and P. D. Olivo.
1994.
Infection of sympathetic and sensory neurons with herpes simplex virus does not elicit a shut-off of cellular protein synthesis: implications for viral latency and herpes vectors.
Neurobiol. Dis.
1:83-94[CrossRef][Medline].
|
| 47.
|
Ogle, W. O.,
T. I. Ng,
K. L. Carter, and B. Roizman.
1997.
The UL13 protein kinase and the infected cell type are determinants of posttranslational modification of ICP0.
Virology
235:406-413[CrossRef][Medline].
|
| 48.
|
O'Hare, P.,
C. R. Goding, and A. Haigh.
1988.
Direct combinatorial interaction between a herpes simplex virus regulatory protein and a cellular octamer-binding factor mediates specific induction of virus immediate-early gene expression.
EMBO J.
7:4231-4238[Medline].
|
| 49.
|
O'Hare, P., and G. S. Hayward.
1985.
Evidence for a direct role for both the 175,000- and 110,000-molecular-weight immediate-early proteins of herpes simplex virus in the transactivation of delayed-early promoters.
J. Virol.
53:751-760[Abstract/Free Full Text].
|
| 50.
|
O'Rourke, D.,
G. Elliott,
M. Papworth,
R. Everett, and P. O'Hare.
1998.
Examination of determinants for intranuclear localization and transactivation within the RING finger of herpes simplex virus type 1 IE110k protein.
J. Gen. Virol.
79:537-548[Abstract].
|
| 51.
|
Quinlan, M. P., and D. M. Knipe.
1985.
Stimulation of expression of a herpes simplex virus DNA-binding protein by two viral functions.
Mol. Cell. Biol.
5:957-963[Abstract/Free Full Text].
|
| 52.
|
Roizman, B., and A. Sears.
1996.
Herpes simplex viruses and their replication, p. 2231-2295.
In
B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, M. S. Hirsch, J. L. Melnick, T. P. Monath, and B. Roizman (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven, Philadelphia, Pa.
|
| 53.
|
Roizman, B., and A. E. Sears.
1993.
Herpes simplex viruses and their replication, p. 11-68.
In
B. Roizman, R. J. Whitley, and C. Lopez (ed.), The Human herpesviruses. Raven Press, New York, N.Y.
|
| 54.
|
Sacks, W. R., and P. A. Schaffer.
1987.
Deletion mutants in the gene encoding the herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell culture.
J. Virol.
61:829-839[Abstract/Free Full Text].
|
| 55.
|
Samaniego, L. A.,
L. Neiderhiser, and N. A. DeLuca.
1998.
Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins.
J. Virol.
72:3307-3320[Abstract/Free Full Text].
|
| 56.
|
Scheck, A. C.,
B. Wigdahl,
E. De Clercq, and F. Rapp.
1986.
Prolonged herpes simplex virus latency in vitro after treatment of infected cells with acyclovir and human leukocyte interferon.
Antimicrob. Agents Chemother.
29:589-593[Abstract/Free Full Text].
|
| 57.
|
Shiraki, K., and F. Rapp.
1986.
Establishment of herpes simplex virus latency in vitro with cycloheximide.
J. Gen. Virol.
67:2497-2500[Abstract/Free Full Text].
|
| 58.
|
Stow, N. D., and E. C. Stow.
1986.
Isolation and characterization of a herpes simplex virus type 1 mutant containing a deletion within the gene encoding the immediate early polypeptide Vmw110.
J. Gen. Virol.
67:2571-2585[Abstract/Free Full Text].
|
| 59.
|
Vahlne, A.,
B. Nystrom,
M. Sandberg,
A. Hamberger, and E. Lycke.
1978.
Attachment of herpes simplex virus to neurons and glial cells.
J. Gen. Virol.
40:359-371[Abstract/Free Full Text].
|
| 60.
|
Ward, P. L., and B. Roizman.
1994.
Herpes simplex genes: the blueprint of a successful human pathogen.
Trends Genet.
10:267-274[CrossRef][Medline].
|
| 61.
|
Weber, P. C.,
J. J. Kenny, and B. Wigdahl.
1992.
Antiviral properties of a dominant negative mutant of the herpes simplex virus type 1 regulatory protein ICP0.
J. Gen. Virol.
73:2955-2961[Abstract/Free Full Text].
|
| 62.
|
Weber, P. C., and B. Wigdahl.
1992.
Identification of dominant-negative mutants of the herpes simplex virus type 1 immediate-early protein ICP0.
J. Virol.
66:2261-2267[Abstract/Free Full Text].
|
| 63.
|
Wrzos, H., and F. Rapp.
1987.
Establishment of latency in vitro with herpes simplex virus temperature-sensitive mutants at nonpermissive temperature.
Virus Res.
8:301-308[CrossRef][Medline].
|
| 64.
|
Zhu, Z.,
W. Cai, and P. A. Schaffer.
1994.
Cooperativity among herpes simplex virus type 1 immediate-early regulatory proteins: ICP4 and ICP27 affect the intracellular localization of ICP0.
J. Virol.
68:3027-3040[Abstract/Free Full Text].
|
| 65.
|
Zhu, Z., and P. A. Schaffer.
1995.
Intracellular localization of the herpes simplex virus type 1 major transcriptional regulatory protein, ICP4, is affected by ICP27.
J. Virol.
69:49-59[Abstract].
|
Journal of Virology, November 2000, p. 10132-10141, Vol. 74, No. 21
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Terry-Allison, T., Smith, C. A., DeLuca, N. A.
(2007). Relaxed Repression of Herpes Simplex Virus Type 1 Genomes in Murine Trigeminal Neurons. J. Virol.
81: 12394-12405
[Abstract]
[Full Text]
-
Frampton, A. R. Jr., Stolz, D. B., Uchida, H., Goins, W. F., Cohen, J. B., Glorioso, J. C.
(2007). Equine Herpesvirus 1 Enters Cells by Two Different Pathways, and Infection Requires the Activation of the Cellular Kinase ROCK1. J. Virol.
81: 10879-10889
[Abstract]
[Full Text]
-
Morishige, N., Jester, J. V., Naito, J., Osorio, N., Wahlert, A., Jones, C., Everett, R. D., Wechsler, S. L., Perng, G. C.
(2006). Herpes simplex virus type 1 ICP0 localizes in the stromal layer of infected rabbit corneas and resides predominantly in the cytoplasm and/or perinuclear region of rabbit keratocytes.. J. Gen. Virol.
87: 2817-2825
[Abstract]
[Full Text]
-
Kwon, H., Bai, Q., Baek, H.-J., Felmet, K., Burton, E. A., Goins, W. F., Cohen, J. B., Glorioso, J. C.
(2006). Soluble V Domain of Nectin-1/HveC Enables Entry of Herpes Simplex Virus Type 1 (HSV-1) into HSV-Resistant Cells by Binding to Viral Glycoprotein D. J. Virol.
80: 138-148
[Abstract]
[Full Text]
-
Frampton, A. R. Jr., Goins, W. F., Cohen, J. B., von Einem, J., Osterrieder, N., O'Callaghan, D. J., Glorioso, J. C.
(2005). Equine Herpesvirus 1 Utilizes a Novel Herpesvirus Entry Receptor. J. Virol.
79: 3169-3173
[Abstract]
[Full Text]
-
Jiang, C., Wechuck, J. B., Goins, W. F., Krisky, D. M., Wolfe, D., Ataai, M. M., Glorioso, J. C.
(2004). Immobilized Cobalt Affinity Chromatography Provides a Novel, Efficient Method for Herpes Simplex Virus Type 1 Gene Vector Purification. J. Virol.
78: 8994-9006
[Abstract]
[Full Text]
-
Jackson, S. A., DeLuca, N. A.
(2003). Relationship of herpes simplex virus genome configuration to productive and persistent infections. Proc. Natl. Acad. Sci. USA
100: 7871-7876
[Abstract]
[Full Text]
-
Burton, E. A., Hong, C.-S., Glorioso, J. C.
(2003). The Stable 2.0-Kilobase Intron of the Herpes Simplex Virus Type 1 Latency-Associated Transcript Does Not Function as an Antisense Repressor of ICP0 in Nonneuronal Cells. J. Virol.
77: 3516-3530
[Abstract]
[Full Text]
-
Jones, C.
(2003). Herpes Simplex Virus Type 1 and Bovine Herpesvirus 1 Latency. Clin. Microbiol. Rev.
16: 79-95
[Abstract]
[Full Text]
-
Luciano, R. L., Wilson, A. C.
(2002). An activation domain in the C-terminal subunit of HCF-1 is important for transactivation by VP16 and LZIP. Proc. Natl. Acad. Sci. USA
99: 13403-13408
[Abstract]
[Full Text]
-
Arthur, J. L., Scarpini, C. G., Connor, V., Lachmann, R. H., Tolkovsky, A. M., Efstathiou, S.
(2001). Herpes Simplex Virus Type 1 Promoter Activity during Latency Establishment, Maintenance, and Reactivation in Primary Dorsal Root Neurons In Vitro. J. Virol.
75: 3885-3895
[Abstract]
[Full Text]